Park­er In­sti­tute-al­lied Tes­sa grabs an $80M round for its next-gen can­cer cell ther­a­pies

Last sum­mer the Park­er In­sti­tute for Can­cer Im­munother­a­py raised eye­brows in R&D cir­cles with its an­nounce­ment that it was al­ly­ing it­self with a lit­tle-known biotech based on Sin­ga­pore that was tak­ing a nov­el ap­proach to adop­tive cell ther­a­pies. Now, the biotech — Tes­sa Ther­a­peu­tics — has raised $80 mil­lion from a well-heeled group that in­cludes the sov­er­eign wealth fund for Sin­ga­pore to fin­ish a Phase III quest aimed at one of the Holy Grails of can­cer R&D.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER